~~<i id='98409BC127'><strike id='98409BC127'><tt id='98409BC127'><pre id='98409BC127'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：comprehensive 2025-09-28 02:28:30 - browse：16522

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： FDA approves updated Covid vaccines

focus

entertainment

explore

focus

leisure time

AdobePatientsoftenasktwoquestionsabouteverymedicaltreatment:Willithelpme?Willithurtme?TheFoodandDrug

WSS

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Addressing health care workers' trauma can help fight burnout

Regeneron agrees to White House price limits on anti

Fentanyl is making it harder to start addiction treatment

H5N1 virus can be tracked in retail milk, scientists say

Private equity could exacerbate cardiology's overuse problem, experts fear

focus

fashion

focus

Sports medicine is finally prioritizing gender equality

Diverse clinical trials: Why aren’t we there yet?

23andMe had bad news about my health. I wish a person had delivered it

New weight loss drugs vying to be the next Wegovy or Mounjaro

Novavax promises a turnaround & Lilly roils the obesity market

IRA could hurt research into orphan drugs for rare diseases

Supreme Court strikes down use of affirmative action

UnitedHealth argues against case alleging wrongful AI care denials

Bright Health sells Medicare Advantage business to Molina

How to make the FDA’s new prescription one

focus

Citing H5N1 threat, CDC urges peak flu monitoring this summer

UnitedHealth argues against case alleging wrongful AI care denials

Cue Health, Covid

Reports of telehealth's death have been greatly exaggerated

New weight loss drugs vying to be the next Wegovy or Mounjaro

Generate Biomedicines machine learning biotech raises $273M

entertainment

explore

focus

leisure time